Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
J Hosp Infect ; 130: 122-130, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36202186

ABSTRACT

BACKGROUND: Limited data are currently available on the incidence rates and risk factors for bacterial sepsis and invasive fungal infections (IFIs) among neonates and infants undergoing major surgery. AIM: To assess the incidence of bacterial sepsis and IFI, fungal colonization, risk factors for sepsis, and mortality in neonates and infants aged <3 months undergoing major surgery. METHODS: A multicentre prospective study was conducted involving 13 level-3 neonatal intensive care units in Italy, enrolling all infants aged ≤3 months undergoing major surgery. FINDINGS: From 2018 to 2021, 541 patients were enrolled. During hospitalization, 248 patients had a bacterial infection, and 23 patients had a fungal infection. Eighty-four patients were colonized by fungal strains. Overall, in-hospital mortality was 2.8%, but this was higher in infected than in uninfected infants (P = 0.034). In multivariate analysis, antibiotic exposure before surgery, ultrasound-guided or surgical placement of vascular catheters, vascular catheterization duration, and gestational age ≤28 weeks were all associated with bacterial sepsis. The risk of IFI was markedly higher in colonized infants (odds ratio (OR): 8.20; P < 0.001) and was linearly associated with the duration of vascular catheterization. Fungal colonization in infants with abdominal surgery increased the probability of IFI 11-fold (OR: 11.1; P < 0.001). CONCLUSION: Preventive strategies such as early removal of vascular catheters and the fluconazole prophylaxis should be considered to prevent bacterial and fungal sepsis in infants undergoing abdominal surgery, and even more so in those with fungal colonization.


Subject(s)
Invasive Fungal Infections , Mycoses , Sepsis , Infant, Newborn , Infant , Humans , Incidence , Prospective Studies , Mycoses/epidemiology , Mycoses/prevention & control , Invasive Fungal Infections/epidemiology , Invasive Fungal Infections/drug therapy , Risk Factors , Sepsis/epidemiology , Sepsis/drug therapy , Antifungal Agents/therapeutic use
2.
Eur J Clin Microbiol Infect Dis ; 34(9): 1797-802, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26024763

ABSTRACT

Macrolides are often used to treat group A streptococcus (GAS) infections, but their resistance rates reached high proportions worldwide. The aim of the present study was to give an update on the characteristics and contemporary prevalence of macrolide-resistant pharyngeal GAS in Central Italy. A total of 592 isolates causing pharyngitis in children were collected in the period 2012-2013. Clonality was assessed by emm typing and pulsed-field gel electrophoresis (PFGE) for all macrolide-resistant strains and for selected susceptible isolates. Genetic determinants of resistance were screened by polymerase chain reaction (PCR). Forty-four GAS were erythromycin-resistant (7.4 %). Among them, 52.3 % and 50 % were clindamycin- and tetracycline-resistant, respectively. erm(B)-positive isolates (52.3 %) expressed the constitutive cMLSB phenotype. mef(A) and its associated M phenotype were recorded in 40.9 % of the cases. The remaining erm(A)-positive isolates expressed the iMLSB phenotype. Seventeen tetracycline-resistant isolates carried tet(M) and five isolates carried tet(O). Twenty-five emm types were found among all strains, with the predominance of emm types 12, 89, 1, and 4. Eleven emm types and 12 PFGE clusters characterized macrolide-resistant strains, with almost two-thirds belonging to emm12, emm4, and emm11. Macrolide-susceptible and -resistant emm types 12, 89, 11, and 4 shared related PFGE profiles. There was a dramatic decline in macrolide resistance in Central Italy among pharyngeal GAS isolates in 2012-2013 when compared to previous studies from the same region (p < 0.05), although macrolide consumption remained stable over the past 15 years. We observed a decrease in the proportion of macrolide-resistant strains within emm types commonly associated with macrolide resistance in the past, namely emm12, 1, and 89.


Subject(s)
Clindamycin/therapeutic use , Drug Resistance, Bacterial/genetics , Erythromycin/therapeutic use , Pharyngitis/drug therapy , Streptococcus pyogenes/drug effects , Tetracycline/therapeutic use , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Child, Preschool , Female , Humans , Italy , Male , Microbial Sensitivity Tests , Pharyngitis/microbiology , Streptococcal Infections/drug therapy , Streptococcal Infections/microbiology , Streptococcus pyogenes/genetics , Streptococcus pyogenes/isolation & purification
3.
Eur J Clin Microbiol Infect Dis ; 33(2): 241-4, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24002218

ABSTRACT

We investigated the prevalence, genetics, and clonality of fluoroquinolone non-susceptible isolates of Streptococcus pyogenes in the central part of Italy. S. pyogenes strains (n = 197) were isolated during 2012 from patients with tonsillopharyngitis, skin, wound or invasive infections and screened for fluoroquinolone non-susceptibility (resistance to norfloxacin and levofloxacin minimum inhibitory concentration (MIC) = 2 mg/L) following EUCAST guidelines. First-step topoisomerase parC and gyrA substitutions were investigated using sequencing analysis. Clonality was determined by pulsed field gel electrophoresis (PFGE; SmaI digestion) and by emm typing. The fluoroquinolone non-susceptible phenotype was identified in 18 isolates (9.1 %) and correlated with mutations in parC, but not in gyrA, the most frequent leading to substitution of the serine at position 79 with an alanine. Most of the fluoroquinolone non-susceptible isolates belonged to the emm-type 6, even if other emm-types were also represented (emm75, emm89, and emm2). A significant level of association was measured between PFGE and both emm type and substitutions in parC. The prevalence of fluoroquinolone non-susceptible Streptococcus pyogenes isolates in Italy is of concern and, although the well-known emm type 6 is dominant, other types are appearing and spreading.


Subject(s)
Anti-Bacterial Agents/pharmacology , Drug Resistance, Bacterial , Levofloxacin/pharmacology , Streptococcal Infections/epidemiology , Streptococcus pyogenes/drug effects , Adolescent , Adult , Child , Child, Preschool , DNA Gyrase/genetics , DNA Topoisomerase IV/genetics , Electrophoresis, Gel, Pulsed-Field , Humans , Infant , Italy/epidemiology , Microbial Sensitivity Tests , Molecular Epidemiology , Molecular Typing , Prevalence , Sequence Analysis, DNA , Streptococcus pyogenes/classification , Streptococcus pyogenes/genetics , Streptococcus pyogenes/isolation & purification
4.
J Proteomics ; 97: 69-87, 2014 Jan 31.
Article in English | MEDLINE | ID: mdl-24145144

ABSTRACT

The application of proteomics to translational and clinical microbiology is one of the most advanced frontiers in the management and control of infectious diseases and in the understanding of complex microbial systems within human fluids and districts. This new approach aims at providing, by dedicated bioinformatic pipelines, a thorough description of pathogen proteomes and their interactions within the context of human host ecosystems, revolutionizing the vision of infectious diseases in biomedicine and approaching new viewpoints in both diagnostic and clinical management of the patient. Indeed, in the last few years, many laboratories have matured a series of advanced proteomic applications, aiming at providing individual proteome charts of pathogens, with respect to their morph and/or cell life stages, antimicrobial or antimycotic resistance profiling, epidemiological dispersion. Herein, we aim at reviewing the current state-of-the-art on proteomic protocols designed and set-up for translational and diagnostic microbiological purposes, from axenic pathogens' characterization to microbiota ecosystems' full description. The final goal is to describe applications of the most common MALDI-TOF MS platforms to advanced diagnostic issues related to emerging infections, increasing of fastidious bacteria, and generation of patient-tailored phylotypes. This article is part of a Special Issue entitled: Trends in Microbial Proteomics.


Subject(s)
Bacteria/metabolism , Communicable Diseases, Emerging/metabolism , Drug Resistance, Bacterial , Drug Resistance, Fungal , Fungi/metabolism , Microbiota , Proteomics/methods , Animals , Bacteria/genetics , Communicable Diseases, Emerging/drug therapy , Communicable Diseases, Emerging/genetics , Communicable Diseases, Emerging/microbiology , Fungi/genetics , Humans , Proteomics/trends
5.
Int J Immunopathol Pharmacol ; 26(2): 463-72, 2013.
Article in English | MEDLINE | ID: mdl-23755761

ABSTRACT

We investigated the clonal relatedness of seven multi-drug-resistant (MDR) Klebsiella pneumoniae isolates, as well as three susceptible K. pneumoniae isolates collected during hospital outbreaks and outbreak-related microbiological surveillance, respectively. The relatedness among K. pneumoniae isolates was assessed by pulsed field gel electrophoresis (PFGE) and automated repetitive-sequence-based PCR (rep-PCR) genotyping and the results were compared to a proteomic phenotyping performed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). All typing methods agreed on the generation of three different clusters of K. pneumoniae isogenetic/related MDR strains. After strengthening hospital infection control measures, no other spreading events involving MDR-K. pneumoniae were reported until the end of the observation period. This preliminary investigation suggests that, in a hierarchical approach to bacterial typing, MALDI-TOF MS proteome profiling might offer a fast and valuable preliminary screening tool able to support microbiologists during nosocomial outbreak surveys.


Subject(s)
Cross Infection/microbiology , Disease Outbreaks , Drug Resistance, Multiple, Bacterial , Hospitals, Pediatric , Klebsiella Infections/microbiology , Klebsiella pneumoniae/isolation & purification , Anti-Bacterial Agents/therapeutic use , Bacterial Typing Techniques/methods , Cross Infection/diagnosis , Cross Infection/epidemiology , Cross Infection/prevention & control , Disease Outbreaks/prevention & control , Drug Resistance, Multiple, Bacterial/genetics , Electrophoresis, Gel, Pulsed-Field , Genotype , Humans , Infection Control/methods , Klebsiella Infections/diagnosis , Klebsiella Infections/epidemiology , Klebsiella Infections/prevention & control , Klebsiella pneumoniae/classification , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/genetics , Microbial Sensitivity Tests , Phenotype , Polymerase Chain Reaction , Proteomics/methods , Rome/epidemiology , Severity of Illness Index , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
SELECTION OF CITATIONS
SEARCH DETAIL
...